Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

IGF-1 · Endocrine

Mecasermin (Increlex)

Recombinant human IGF-1 for severe primary IGF-1 deficiency.

FDA-Approved

Plain-Language Label Highlights

Brand names: Increlex

What it's approved for

Severe primary IGF-1 deficiency in children and GH gene deletion with anti-GH antibodies.

A twice-daily injection of recombinant IGF-1 — given with a meal — that supports growth in children whose bodies don't make IGF-1.

Common side effects
  • Hypoglycemia (must take with food)
  • Tonsillar hypertrophy / snoring
  • Injection-site lipohypertrophy
  • Ear infections
Serious risks to know
  • Severe hypoglycemia
  • Intracranial hypertension
  • Tonsillar enlargement leading to sleep apnea
  • Theoretical increase in benign and malignant neoplasms
Who should avoid or use with extra caution
  • Active or suspected cancer
  • Closed epiphyses (when used for growth)
  • Allergy to mecasermin

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.

Research Areas

Severe primary IGF-1 deficiency
Growth failure with GH gene deletion and neutralizing GH antibodies

Common Research Protocols

Twice-daily SC

0.04–0.12 mg/kg SC twice daily, given with a meal/snack.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]JCEM·2007

Mecasermin in severe primary IGFD

Improved height velocity over multi-year follow-up.

Important Considerations

  • FDA-approved.
  • Hypoglycemia — must be taken with food.
  • Tonsillar hypertrophy, intracranial hypertension reported.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Mecasermin (Increlex)

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.